TORNTPHARM

Torrent Pharma continues to show steady growth driven by strong performance in India, Brazil, and Germany. Its focus on chronic therapies like cardiovascular and CNS provides earnings stability. Margins remain healthy due to a strong branded portfolio. While US exposure is limited compared to peers, this also reduces regulatory risk. Torrent remains a high-quality, low-volatility pharma stock suited for conservative investors looking for steady compounding rather than aggressive growth.